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ABSTRACT 
Obesity is associated with a mild inflammation and altered protein secretion in adipose 
tissue. These changes have been suggested to contribute to the development of obesity-
associated disorders including, insulin resistance, dyslipidemia, type 2 diabetes and 
cardiovascular disease. 
 
The aim of this thesis was to identify novel factors expressed in the adipose tissue that 
could be important in the development of obesity and obesity-associated disorders. 
 
In paper I we studied the transcriptional control of the human CIDEA gene and the 
effects of TNFα. CIDEA has previously been shown to be differentially expressed in 
lean and obese subjects and repressed by tumor necrosis factor α (TNFα), however the 
human CIDEA promoter has not been investigated. Reporter assays demonstrated that 
the minimal transcriptional activity of the human CIDEA promoter was confined to a 
region 97 bp upstream of the transcriptional start site (TSS). TNFα attenuated the 
transcriptional activity of CIDEA and this regulation was confined to a region between 
244 and 123 bp upstream of the TSS. Electrophoretic mobility shift assays and 
mutational analysis suggested that the regulation by TNFα is mediated by a nuclear 
factor (NF)-κB binding site. 
 
In paper II and III we investigated the function of the twist1 gene in human white 
adipocytes and its relationship with obesity. Twist1 is involved in various processes, 
such as bone development, cancer progression, inflammation and brown adipose tissue 
function, but the role in white adipose tissue is not known. In paper II we assessed the 
expression of twist1 in human white adipose tissue, liver, skeletal muscle and pancreas 
as well as in different cell types in adipose tissue. Twist1 mRNA expression was 
significantly higher in adipose tissue compared to the other organs and within adipose 
tissue; the expression was highest in the adipocyte fraction. In vitro silencing of twist1 
by RNA interference was used to investigate the role of twist1 in lipid turnover and 
inflammation in human adipocytes. In contrast to mice where twist1 reduces fatty acid 
oxidation, reduction of twist1 expression in human in vitro differentiated adipocytes 
lead to a reduction in fatty acid oxidation. Furthermore, expression of the rate-limiting 
enzyme for fatty acid oxidation, carnitine palmitoyl transferase 1, was also reduced 
when twist1 was silenced, suggesting that twist1 is required for fatty acid oxidation in 
human white adipocytes. We were also able to demonstrate that twist1 regulates the 
expression of inflammatory proteins, including interleukin (IL) -6 and monocyte 
chemoattractant protein 1. Chromatin immunoprecipitation demonstrated direct binding 
to sequences in the promoter regions of these genes. In paper III, we further explored 
the expression of twist1 in non-obese and obese subjects and correlated the expression 
with different clinical parameters of insulin resistance. Interestingly and in contrast to 
studies in mice, low twist1 expression associated with a higher BMI and a more 
adverse clinical profile, characterized by higher HOMA-IR values, large adipocytes and 
an increased secretion of pro-inflammatory factors. We also assessed the effect of 
twist1 silencing on TNFα-induced cytokine and chemokine expression and secretion in 
human adipocytes. Twist1 knockdown accentuated the pro-inflammatory effects of 
TNFα- suggesting that twist1 may have a protective role in adipose inflammation.  
  
 
In conclusion, we have defined the minimal promoter needed for transcription of 
human CIDEA and a region in the promoter regulated by TNFα. We have also 
demonstrated that twist1 is expressed in white adipocytes and that low expression of 
twist1 associates with high BMI, markers of insulin resistance and an increased 
secretion of pro-inflammatory factors. Additionally, silencing of twist1 in human in 
vitro differentiated adipocytes demonstrates a role for this transcription factor in fatty 
acid oxidation and inflammation. We hypothesize that low twist1 expression in obesity 
renders the adipose tissue more vulnerable to the pro-inflammatory effects of TNFα, 
which could be of importance in the development of obesity-associated insulin 
resistance and type 2 diabetes. 
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1 INTRODUCTION 
The aim of this thesis was to investigate the function of two genes, twist1 and cell death-
inducing DNA fragmentation factor (DFF)-α-like effector A (CIDEA), in human adipose 
tissue and the role of these two factors in obesity. In the following section I have 
summarized the most important concepts in the study of obesity and adipose tissue in the 
development of obesity-associated disorders like insulin resistance, hyperlipidemia, type 
2-diabetes and cardiovascular disease.   
 
 
1.1 OBESITY AND ASSOCIATED COMPLICATIONS 
During the last decades the incidence of obesity has accelerated in the world, reaching 
epidemic proportions. In 2008, the World Health Organization (WHO) estimated that 1.5 
billion adults in the world were overweight and approximately 500 million adults were 
obese. Along with obesity, the prevalence of insulin resistance and type 2 diabetes are 
also increasing leading to huge economical consequences. Moreover, obesity is associated 
with increased risk for hypertension, dyslipidemia, fatty liver disease, and cardiovascular 
disease as well as cancer. Given the vast number of pathologies linked to obesity there is a 
great need for understanding the association between obesity and its complications.  
 
Body mass index (BMI) is defined as a subject’s body weight (in kg) divided by the 
square of the subject’s height (in m). It is an index which is used for classifying normal-, 
under-, and overweight. According to the World Health Organization (WHO), obesity is 
defined as a BMI equal to or greater than 30 kg/m2 while a BMI equal to or above 25 
kg/m2 is defined as overweight. The BMI cut-off for obesity and overweight are based on 
epidemiological studies and the risk of developing cardiovascular disease1-4. The BMI 
classes are detailed in Table 1. Other methods for determining body fat and body 
composition include waist-to-hip ratio or waist circumference, which are fairly good and 
simple methods for assessing central (intra-abdominal) obesity. Bioelectrical impedance 
measurements estimate fat as well as the fat-free mass based on the conductivity of the 
body. Dual Energy X-ray Absorptiometry (DEXA) scanning gives an estimate of fat 
mass, muscle mass and bone mass. Underwater weighing provides information about fat 
mass and lean body mass (muscle and bone) and is considered the gold standard for 
assessment of body composition. However for obvious reasons it is rather complicated 
and time-consuming. Compared to DEXA, underwater weighing and bioelectrical 
impedance, BMI measurements have the advantage of being both simple and cheap. 
Therefore BMI together with waist-to-hip ratio and waist circumference are the most 
commonly employed techniques in routine clinical use. The limitation with BMI is that 
certain groups of patients, including children, elderly people, and highly trained athletes, 
cannot be categorized according to this index. 
 
At its simplest level, obesity develops when energy intake exceeds energy expenditure. 
These processes are regulated by both genetic and environmental factors. Monogenic 
causes of obesity are rare, affecting less than 1% of the obese subjects and are often 
caused by mutations in genes expressed in the hypothalamus, which are involved in the 
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control of food intake. Such mutations are typically located in the coding region of these 
genes and cause dramatic effects on the gene function. Susceptibility genes increase the 
risk for developing common forms of obesity and are associated with single-nucleotide 
polymorphisms (SNPs) in both the non-coding and the coding region of genes. In contrast 
to the dramatic effects of mutations seen in monogenic obesity, obesity-susceptibility 
genes only explain a small percentage of the variation in body weight and genome-wide 
association studies of susceptibility genes have hitherto been somewhat disappointing. 
Furthermore, the rapid increase in obesity prevalence has made it clear that genetic factors 
cannot be the only determinants of adiposity. Nevertheless, from an evolutionary 
perspective, gene variants favoring energy storage have clearly conferred a survival 
advantage to mankind. However in the obesogenic environment of our modern society, 
with easy access to energy-rich food combined with a sedentary life style, these variants 
have become maladaptive.  
 
 
Table1. BMI classes according to WHO. 
Classification BMI 
Underweight < 18.5 
Normal weight 18.5 - 24.9 
Overweight ≥ 25 
Pre-obese 25.0 - 29.9 
Obese ≥ 30 
Obese class I 30 - 34.9 
Obese class II 35.0 - 39.9 
Obese class III ≥ 40 
 
 
1.2 ADIPOSE TISSUE  
White adipose tissue (WAT) is a loose connective tissue composed of adipocytes and a 
stroma-vascular fraction that contains adipocyte precursor cells, also termed 
preadipocytes; leukocytes, including adipose-tissue macrophages (ATM), lymphocytes, 
and mast cells; as well as fibroblasts and endothelial cells. WAT is found in numerous 
parts of the body but the largest depots in humans are the subcutaneous (sc), and the 
visceral (vis, subdivided in the omental and the mesenteric) depots. The two adipose 
depots display different properties, which will be discussed later. Another type of adipose 
tissue is the brown adipose tissue, primarily found in hibernating mammals, newborn 
infants and to a much lesser extent in human adults. In contrast to WAT, the main 
function of brown adipose tissue is to generate heat via lipid oxidation. During the last 
few years it has become clear that adult humans possess active brown fat and the 
possibility of activating this tissue has gained increasing attention in obesity research5-7. 
One area of particular interest is the conversion of white adipocytes into more brown-like 
adipocytes, which would favor energy expenditure instead of energy storage8. However, 
the studies presented in this thesis have exclusively been performed in WAT. 
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1.3 FUNCTION OF WHITE ADIPOSE TISSUE  
The main functions of WAT are to insulate the body and store energy during periods of 
food abundance. In the adipocytes, energy is stored in the form of triacylglycerols 
(TAGs), composed of three fatty acids esterified to one molecule of glycerol. When the 
body needs energy, e.g. after an over-night fast or during prolonged exercise, TAGs can 
be hydrolyzed into non-esterified fatty acids (NEFAs) and released into the circulation. In 
the blood, NEFAs are bound to albumin and transported to target tissues, including 
skeletal muscle and liver, where they are used as energy substrates. Until the early-1990s, 
WAT was generally regarded as an energy-storing and insulating organ. Following the 
discovery of adipose-derived hormones like leptin, TNFα and many others, it has become 
clear that adipose tissue is an endocrine organ, which secretes factors collectively termed 
adipokines9,10. Adipokines can act on the adipose tissue itself in an auto- and/or paracrine 
fashion or be released into the circulation to regulate other organs including, skeletal 
muscle, liver and the central nervous system (CNS). This emphasizes the role of adipose 
tissue as an important regulator of whole body metabolism and also explains why an 
abnormal expansion of adipose tissue can have such detrimental effects on other 
metabolically important tissues.  
 
In obesity, release of NEFAs and adipokines from the adipose tissue is altered, which 
leads to disturbances in metabolically important organs like skeletal muscle, pancreas and 
liver. Such alterations will eventually cause impaired whole-body insulin sensitivity 
which is manifested by reduced insulin-stimulated glucose uptake in skeletal muscle, 
reduced insulin secretion from pancreatic β-cells and increased lipid and glucose output 
from the liver11.  
 
In the following sections I will focus on the processes by which adipocytes release and 
synthesize TAGs, how these processes are regulated as well as some of the most 
important adipokines and concepts in the development of obesity-associated 
complications. In the final two sections I will introduce the two genes that have been the 
focus of the studies in this thesis. 
 
 
1.4 LIPOGENESIS AND LIPOLYSIS 
TAGs from the diet are hydrolyzed by pancreatic lipases into monoacylglycerols (MAGs) 
and NEFAs, which together with bile salts form micelles that are transported in the 
intestine to the absorptive cells. NEFAs and MAGs from the micelles are subsequently 
taken up, by passive diffusion or fatty acid transporters, into the enterocytes in the small 
intestine. Inside the enterocyte MAGs and NEFAs are re-esterified into TAGs and 
packaged with phospholipids and proteins, to form particles termed chylomicrons. Upon 
exit from the enterocytes, chylomicrons pass into lymphatic capillaries termed lacteals, 
subsequently into larger branches of the lymphatic systems and ultimately into the 
circulation that transport them to target tissues including WAT. At the adipocyte cell 
membrane, lipoprotein lipase (LPL) binds to chylomicrons and hydrolyzes TAGs into 
NEFAs that are taken up by the adipocyte through fatty acid transporters 
(FAT/FATP/FABP). LPL can also hydrolyze TAGs transported in circulating very low 
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density lipoprotein (VLDL) particles, which are produced in and released by the liver. 
Inside the adipocyte, NEFAs are activated by the addition of a coenzyme A (CoA) 
molecule, a process which is catalyzed by the enzyme fatty acyl–CoA synthetase (ACS). 
Three activated NEFAs are then coupled to one molecule of glycerol 3-phosphate in a 
process termed lipogenesis. Glycerol is synthesized from glucose that is taken up by 
glucose transporters (GLUT1 and -4) in the adipocyte cell membrane. Glucose is 
converted to dihydroxyacetone (DHAP) via the glycolytic pathway and DHAP is 
subsequently reduced to glycerol 3-phosphate by the enzyme glycerol phosphate 
dehydrogenase. Glycerol 3-phosphate can also be generated from circulating glycerol by 
the enzyme glycerol-3-kinase; however, this enzyme is expressed at very low levels in 
adipocytes. In addition, glucose intermediates, derived via glycolysis, can be used for the 
synthesis of NEFAs in a process termed de novo lipogenesis. 
 
The regulated enzymatic hydrolysis of TAGs is termed lipolysis. In lipolysis, NEFAs are 
released from the glycerol backbone in a three-step process. The first step is catalyzed by 
an enzyme termed adipose triglyceride lipase (ATGL) or desnutrin12, which generates one 
NEFA and a diacylglycerol (DAG) molecule. In the second step, DAG is hydrolyzed by 
hormone-sensitive lipase (HSL)13 generating another NEFA molecule and a MAG 
molecule. HSL is the rate-limiting enzyme for human lipolysis and exhibits both DAG 
and TAG hydrolase activity although the activity towards DAG is approximately ten 
times higher than that on TAG14. This is in contrast to ATGL, which selectively uses 
TAGs as substrates14,15. In the final step, the remaining MAG is hydrolyzed by 
monoacylglycerol lipase (MAGL) into one NEFA and one glycerol molecule. NEFAs, 
hydrolyzed through lipolysis and released into the blood, are primarily taken up by 
skeletal muscle for fatty acid oxidation (β-oxidation) or by the liver for synthesis of TAGs 
and lipoprotein particles (e.g. VLDL). As previously mentioned, due to the low 
expression of glycerol-3-kinase, glycerol obtained from adipocyte lipolysis cannot be 
used by the adipocyte itself but is instead transported to the liver where it is 
phosphorylated by glycerol-3-kinase. Glycerol 3-phosphate is then used for TAG 
synthesis, glycolysis or gluconeogenesis in the liver. For a more comprehensive overview 
of lipolysis and lipogenesis see biochemistry books, e.g.16,17, or the following reviews18,19.   
 
 
1.5 REGULATION OF LIPOLYSIS 
In mammal adipocytes, there is a constant low level of lipolysis termed basal or 
spontaneous lipolysis. However, under the influence of specific hormones, lipolysis can 
be induced or inhibited to a very significant degree. The most important endogenous 
regulators are catecholamines (noradrenaline and adrenaline), natriuretic peptides and 
insulin (reviewed in18,19). The activity of HSL, and thus lipolysis, is tightly controlled by 
catecholamines, signaling through adrenergic receptors on the adipocyte cell membrane. 
There are four different adrenergic receptors on the human adipocyte, β1, β2, β3 and 
α2A. β1, β2 and α2Α are the most important adrenergic receptors in human fat cells 
whereas β3 plays a more important role in rodents. The β-receptors are coupled to 
stimulatory GTP-binding proteins (Gs), which upon β-receptor ligand-binding, activate 
adenylate cyclase (AC) causing an increase in cyclic adenosine monophosphate (cAMP) 
formation and a subsequent activation of protein kinase A (PKA). PKA, in turn, 
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phosphorylates HSL which leads to its activation and a redistribution of HSL from the 
cytoplasm to the lipid droplet surface. In addition, PKA also phosphorylates the lipid-
coating phosphoprotein perilipin A (PLIN)20. This changes the conformation of PLIN and 
leads to the recruitment of activated HSL to the lipid droplet surface for subsequent TAG 
hydrolysis21. Furthermore, PKA phosphorylation of PLIN releases another lipid-droplet 
coating protein termed comparative gene identification (CGI) -58. CGI-58 is a cofactor 
for ATGL and is needed for the full activation of ATGL22,23. In its unphosphorylated 
state, PLIN probably works as a barrier for TAG hydrolysis on the lipid droplet and 
inhibits CGI-58-dependent activation of ATGL. Taken together, the activation of PKA 
leads to an increase in lipolysis. In contrast to the β-receptors, the α2A-receptors are 
coupled to inhibitory G proteins (Gi) that inactivate AC, which reduces cAMP levels 
thereby causing a decrease in PKA activation and lipolysis. This regulation by α2A-
receptors is specific for primates and provides another level of fine-tuning of the lipolytic 
response. Moreover, adrenaline has a higher affinity for α2A-receptors suggesting that 
these receptors might be especially prominent during situations of stress or after exercise 
when adrenaline levels are high.  In conclusion, the net effect of catecholamines on 
lipolysis in human fat cells depends on the relative expression and function of α2A- 
versus β-receptors.  
 
Apart from catecholamines, natriuretic peptides are also potent activators of lipolysis in 
humans and primates. They act by binding to the natriuretic peptide receptor A (NPR-A), 
which possesses guanylyl cyclase (GC) activity. Activation of GC increases the cyclic 
guanosine monophosphate (cGMP) concentrations in the cell and cGMP binds and 
activates protein kinase G (PKG). PKG in turn, phosphorylates HSL and PLIN, thus 
activating lipolysis. 
 
The most potent anti-lipolytic agent is insulin. Insulin binding to the insulin receptor (IR) 
induces a conformational change that results in auto-phosphorylation of several tyrosine 
residues in the receptor (for reviews on insulin signaling, see24,25). The phosphorylated 
tyrosine residues in the IR provide docking sites for proteins with Src homology (SH) 2 
domains, including insulin receptor substrates (IRS)-1 and -2, which are also activated by 
tyrosine phosphorylation. The tyrosine phosphorylated IRS-1 and -2 then activate a 
phosphatidylinositol (PI) 3-kinase complex that catalyzes the formation of 
phosphatidylinositol (3,4,5) triphosphate (PIP3), which in turn activates Pleckstrin 
homology (PH) domain-containing proteins like 3-phosphoinositide dependent protein 
kinase-1 (PDK1). PDK1 activates the downstream effectors Akt or PKB and atypical 
isoforms of PKC (PKCζ and PKCλ), which results in enhanced translocation of GLUT4 
to the plasma membrane and an increased glucose uptake. Moreover, Akt phosphorylates 
phosphodiesterase 3B (PDE3B) thereby increasing the breakdown of cAMP to 5’AMP 
and reducing the activity of PKA and HSL. In addition to these pathways, insulin also 
induces glycogen synthesis in skeletal muscle and liver, increases lipogenesis in liver and 
WAT, and increases protein synthesis, cell differentiation and proliferation25.  
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Figure1. Lipolysis regulation in human adipocytes. α2/β-AR, α2/β-adrenergic receptor; AC, adenylyl cyclase; AMP, 
adenosine monophosphate; ANP, atrial natriuretic peptide; ATGL, adipose triglyceride lipase; ATP, adenosine 5’-
triphosphate; AQP, aquaporine; cAMP, cyclic AMP; CGI-58, comparative gene identification-58; cGMP, cyclic guanosine 
monophosphate; DAG, diacylglycerol; FATP, fatty acid transport protein; Gi/s, inhibitory/stimulatory GTP-binding 
protein; GC, guanylyl cyclase; GLUT4, glucose transporter 4; GTP, guanosine triphosphate; HSL, hormone sensitive 
lipase; IR, insulin receptor; IRS, insulin receptor substrate; JNK, c-Jun N-terminal kinase; MAG, monoacylglycerol; MAGL, 
monoacylglycerol lipase; NEFA, non-esterified fatty acid; NPR-A, natriuretic peptide receptor A; PDE3B, 
phosphodiesterase3B; PLIN, perilipin A; PKA, protein kinase A; PKG, protein kinase G; TAG, triacylglycerol; TNFα, tumor 
necrosis factor α; TNFR, TNFα receptor. 
 
 
There are several other regulators of lipolysis although the effects are smaller than for the 
above mentioned hormones. Prostaglandin E2 (PGE2) activates Gi and thus displays anti-
lipolytic effects in adipocytes. Tumor necrosis factor α (TNFα) increases basal or 
spontaneous lipolysis in adipocytes by stimulating MAP kinases that among many other 
effects cause phosphorylation of PLIN (described in more detail below). Lipolysis 
regulation is summarized in Figure 1. 
 
 
1.6 DYSREGULATION OF LIPOLYSIS IN OBESITY 
Obesity is characterized by an increased basal but decreased stimulated lipolysis; 
however, there are regional differences in lipolysis. Basal lipolysis is increased in all 
adipose depots in obesity partly due to increased fat cell size and partly due to increased 
concentrations of TNFα18. In contrast; there are large variations in stimulated lipolysis in 
subcutaneous (sc) and visceral (vis) WAT. Thus, in obesity, stimulated lipolysis is 
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decreased in sc WAT. This is due to an increased expression of α2Α receptors and a 
combined reduction in the expression of β2-receptors and HSL leading to a resistance to 
the lipolytic effect of catecholamines18,26. In contrast, in vis WAT, stimulated lipolysis is 
increased, which is due to an increased expression of β3-adrenoreceptors with a 
concomitant decrease in α2A-adrenoreceptors expression27. These regional differences in 
stimulated lipolysis lead to a redistribution of NEFAs during catecholamine stimulation so 
that NEFAs are primarily released from the vis depots. Although the vis adipose depots is 
significantly smaller than the sc depot the vis depot drains directly to the liver via the 
portal vein, which has detrimental consequences in obesity. NEFAs delivered to the liver 
are used for the synthesis of VLDL particles and to some extent glucose, which both 
contribute to impaired insulin action in peripheral organs. NEFAs released from the sc 
depots on the other hand can be transported via peripheral veins to skeletal muscle and 
pancreas. In skeletal muscle, NEFAs are preferentially taken up and used as energy 
substrate instead of glucose thereby reducing glucose uptake during insulin stimulation. In 
the pancreas, chronically elevated levels of circulating NEFAs lead to a reduced secretion 
of insulin. Altogether, the increased levels of NEFAs in the circulation impair insulin 
action in several organs leading to peripheral insulin resistance. Results in recent years 
have also demonstrated that NEFAs can act on insulin sensitivity mechanism by 
activating toll-like receptors (TLR)28. These receptors are involved in immunological 
responses and activation of TLRs induces an intracellular signaling cascade that activates 
pro-inflammatory cytokines (e.g. TNFα and interleukin (IL)-6)28. Moreover, NEFAs can 
also indirectly, by esterification to DAGs, activate isoforms of PKC, which in turn leads 
to phosphorylation of serine residues on IRS-1 and inhibition of insulin signaling29.  
 
 
1.7 ADIPOSE TISSUE INFLAMMATION 
During the last decade it has been conclusively shown that obesity is associated with a 
chronic low-grade inflammation in WAT, which is tightly coupled to a functional 
dysregulation of the tissue30,31. It is now generally considered that the alterations in WAT 
function lead to changes in the release of adipokines as well as NEFAs, increasing the risk 
of developing obesity-associated complications11,32-34.  
 
ATMs are important regulators of WAT inflammation. In the WAT from lean, insulin-
sensitive subjects, ATMs are probably involved in normal WAT turnover by clearing the 
tissue from apoptotic cells, lipids and cellular debris. These ATMs, primarily serving as 
scavenger cells, secrete cytokines with anti-inflammatory properties (e.g. IL-10) and have 
been termed M2-ATMs35. In contrast, in the obese state, monocytes are recruited from the 
circulation and accumulate in the expanding WAT where they, through unclear 
mechanisms, undergo polarization into a class of macrophages with pro-inflammatory 
properties termed M1-ATMs36,37. These cells release high levels of pro-inflammatory 
factors like TNFα, IL-6 and monocyte chemoattractant protein-1 (MCP-1), which attract 
more monocytes from the circulation and at the same time stimulate lipolysis and inhibit 
insulin signaling in the adipocytes.  
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1.8 OTHER PATHOGENIC MECHANISM FOR OBESITY-INDUCED INSULIN 
RESISTANCE 
 
1.8.1 Adipose tissue morphology 
In addition to adipokines and inflammation, the morphology of the adipose tissue has 
significant effects on the function of the tissue. As the adipose tissue enlarges with 
increasing obesity there is a need for re-organization of the tissue structure to permit 
adipocyte expansion. Adipose tissue can expand by an increase in adipocyte volume, 
adipocyte number or both. Recent studies have revealed that adipose tissue expands 
primarily by increasing adipocyte volume whereas adipocyte number, which is set early 
in life, remains relatively constant in adulthood38. However, approximately 10% of fat 
cells are renewed every year indicating that adipose tissue is indeed a plastic organ38. 
Increased adipocyte size correlates with plasma insulin concentrations and small and large 
fat cells display distinct gene expression and secretory patterns39-41. This suggests that 
adipocyte size is an important determinant for adipocyte function and metabolic 
parameters. Instead of adipocyte size, the morphology of the adipose tissue can be 
determined. An adipose morphology value can be calculated based on the difference 
between the observed and the expected adipocyte volume for any given body fat mass42. 
Based on the morphology value, adipose tissue can be divided into hypertrophic, 
characterized by few and large fat cells, or hyperplastic, characterized by many and small 
fat cells. Adipose morphology is influenced by neither sex nor obesity, however a 
hypertrophic adipose tissue associates with increased HOMA-IR values and increased 
fasting plasma insulin levels42. 
 
 
1.8.2 Adipose tissue vascularization and hypoxia 
Adequate vascularization of the adipose tissue is crucial to allow for expansion and 
normal delivery of nutrients to the adipocytes43,44. A relatively new concept in the context 
of adipose tissue function and inflammation is hypoxia44,45. It has been suggested that 
hypoxia manifested by an insufficient supply of blood, and thus oxygen, to the expanding 
adipocytes can induce changes in adipocyte metabolism and initiate an inflammatory 
response. Reduction in oxygen levels can be caused by either inadequate vascularization 
of the expanding tissue, increased diffusion distances caused by increased adipocyte size 
or both. Low oxygen tension in adipocytes induces activation of the transcription factor 
hypoxia inducible factor (HIF)-1, which increases the transcription of IL-6, GLUT1, 
leptin and vascular endothelial growth factor (VEGF) and reduces the expression of 
adiponectin46,47. Hypoxia also leads to a reduction in mitochondrial oxidative 
phosphorylation and adenosine triphosphate (ATP) production forcing the cells to switch 
to anaerobic glycolysis and increased glucose uptake45,48. In addition, reduced oxygen 
tension inhibits preadipocyte differentiation and increases the inflammatory response of 
ATMs49,50. 
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1.9 ADIPOKINES 
As previously mentioned WAT is considered to be an endocrine organ, which secretes 
peptides collectively termed adipokines that act locally or in an endocrine fashion. The 
adipocyte proteome was recently characterized and comprises almost 1500 proteins 
whereas the adipocyte secretome comprises more than 300 specific peptides 51(and 
personal communication with Prof Juergen Eckel, Dusseldorf, Germany). In addition to 
adipocytes, other cells in WAT, including preadipocytes, inflammatory cells, endothelial 
cells as well as other cells can also release a number of adipokines which regulate diverse 
functions such as; inflammation, adipogenesis, proliferation, metabolism, stress and 
vascularization. A complete summary of all adipokines is out of the scope of this thesis 
and I have therefore chosen to focus on the adipokines with relevance for the papers 
presented herein.  
 
 
1.9.1 Leptin 
The first true adipokine to be identified was leptin, the product of the obese gene, which is 
almost exclusively produced by adipocytes9,52. Leptin is a 16 kD cytokine-like protein, 
which signals via a leptin receptor, LEP-R. Alternative splicing of the human leptin 
receptor gene generates at least six isoforms of the receptor (LEP-R a-f) some of which 
are soluble forms present in the circulation. However, only the LEP-Rb isoform contains 
the intracellular signaling domain needed for signal transduction and other isoforms likely 
function by regulating circulating levels of leptin. 
 
Circulating levels of leptin are directly correlated with adipose tissue mass and thus 
increased in obese rodents and humans9,53. Leptin acts on cells in the arcuate nucleus in 
the hypothalamus where it increases energy consumption, reduces appetite and stimulates 
satiety by counteracting orexigenic and stimulating anorexigenic neuropeptides 
respectively11,52. Leptin functions as an adipostat that signals to the brain how much 
energy is stored in the body. Disruption of the leptin (ob/ob) or leptin receptor gene 
(db/db) in mice or defects in the corresponding human genes causes severe obesity9,54. 
Administration of recombinant leptin to leptin-deficient mice or humans restores body 
weight by reducing food intake and increasing metabolic rate52,55. However, apart from 
rare forms of congenital leptin deficiency, leptin treatment is not effective in treating 
common morbid obesity. This is probably due to the fact that, in non-congenital forms of 
obesity leptin levels are already high due to the increase in WAT mass. This implies that 
there may be a general resistance to leptin in common obesity.  
 
 
1.9.2 Adiponectin  
Adiponectin was discovered in 1995 as a 30 kD serum protein exclusively secreted by 
adipocytes56,57. Adiponectin signals via two membrane-bound receptors ADIPOR1 and 
ADIPOR2 expressed primarily in skeletal muscle and liver33. The secreted protein forms 
trimers, hexamers and high molecular weight forms (12-18mers), though the biologically 
active form has been debated. Adiponectin is detected at high levels in the circulation and 
in contrast to many other adipokines, circulating levels of adiponectin are decreased in 
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obesity30,58. Disruption of the adiponectin gene in mice has no effect on body weight but 
induces insulin resistance and an enhanced inflammatory response to vascular injury 
suggesting a role for adiponectin in insulin sensitivity and atherosclerosis59. In line with 
this, low adiponectin levels also correlates with coronary heart disease and type 2 diabetes 
in humans60,61. 
 
Ligand binding to the adiponectin receptors induces phosphporylation of AMPK, which 
in turns increases fatty acid oxidation and glucose uptake in skeletal muscle and reduces 
gluconeogenesis in the liver62. Adiponectin also inhibits the transformation of 
macrophages to lipid filled foam cells and acts as an anti-inflammatory factor by reducing 
TNFα-stimulated cytokine release and increasing release of the anti-inflammatory 
cytokine IL-10 from macrophages62-66. In addition to its action on macrophages 
adiponectin stimulates endothelial cell migration and differentiation further implicating 
adiponectin as an important link between adipose tissue and cardiovascular tissues67,68. 
 
 
1.9.3 TNFα 
TNFα is a pleiotropic cytokine that regulates cellular and biological processes such as 
immune function, apoptosis, proliferation, differentiation and metabolism (for a review on 
TNFα see 69-71). The protein is synthesized as a 26 kDa transmembrane protein that 
undergoes proteolytic cleavage to yield a secreted 17 kDa molecule. The 17 kDa TNFα 
monomers form trimers that bind to ubiquitously expressed transmembrane TNFα 
receptor 1 and 2 (TNFR1/-2). Like the ligand, TNFRs can be proteolytically cleaved 
generating soluble forms of the receptors. Both receptors activate distinct signaling 
pathways although less is known about the pathways regulated by TNFR2. Upon ligand 
binding, TNFR1 trimerizes and recruits receptor-interacting proteins that in turn convey 
the signal to intracellular key targets eventually leading to changes in gene transcription 
and/or phosphorylation.  
 
TNFα is a potent stimulator of inflammatory pathways69. These signals are primarily 
attributed to NF-κB activation and increased gene transcription of pro-inflammatory 
genes. The role of TNFα in obesity and diabetes was first recognized in 1993 when 
Hotamisligil et al showed that WAT expression, as well as circulating levels of TNFα 
were increased in rodent models of obesity and diabetes10. Moreover, targeted null 
mutation in the gene encoding TNFα in mice ameliorates insulin resistance induced by a 
high fat diet or genetic obesity72. Increased expression and secretion of TNFα from WAT 
in obesity has subsequently been confirmed in humans73. However in contrast to rodents, 
plasma levels of TNFα are extremely low in humans and injection of TNFα blocking 
antibodies have failed to improve insulin sensitivity in type 2 diabetics74,75. These findings 
have led scientist to speculate that TNFα primarily functions as a para- and/or autocrine 
factor in human WAT. The main sources of TNFα in adipose tissue are the non-adipose 
cells in the stroma-vascular fraction, including macrophages76. 
 
At a cellular level, TNFα has been shown to reduce the expression of genes involved in 
insulin signaling, including GLUT4, IR and IRS-1 as well as the transcription factor 
peroxisome proliferator-activated receptor (PPAR)γ77. PPARγ is a central regulator of 
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adipogenesis and controls expression of genes with important functions in adipocytes. In 
addition, TNFα activates a set of different kinases that promotes phosphorylation of 
serine residues on the IR and IRS-1 thereby preventing insulin-induced tyrosine 
phosphorylation of IR and IRS-1 and ultimately insulin signaling77. 
 
TNFα effectively stimulates lipolysis in both human and rodent fat cells78-80. In human 
adipocytes, TNFα reduces the expression of PDE3B, which leads to an increase in cAMP 
levels, activation of PKA and phosphorylation of PLIN81. These effects are mediated via 
the MAP kinases p44/42 and c-Jun N-terminal kinase (JNK)82. NF-κB is also involved in 
TNFα-induced lipolysis, presumably by controlling transcriptional regulation of PLIN 
and HSL mRNA83. In rodent adipocytes, TNFα also induces lipolysis by a reduction in Gi 
expression, however this regulation has not been possible to demonstrate in human 
adipocytes84. In addition to lipolysis, TNFα also reduces fatty acid uptake and oxidation 
as well as expression of electron transport genes85. 
 
 
1.9.4 Interleukin 6 (IL-6) 
IL-6 is a 21 kD pro-inflammatory adipokine produced by both macrophages and 
adipocytes. High plasma levels of IL-6 correlate with obesity and type 2 diabetes whereas 
weight-reduction reduces the plasma levels of this adipokine86. Adipose tissue 
contributes, at least in part, to the circulating levels of IL-6, as adipose tissue releases IL-6 
to the circulation and IL-6 release is higher from omental compared to sc adipose 
tissue86,87. The exact role of IL-6 in insulin resistance is not clear. IL-6 stimulates lipolysis 
in human adipocytes in culture and impairs insulin-induced IR and IRS-1 phosphorylation 
in adipocytes and hepatocytes by activation of suppressor of cytokine signaling (SOCS) 
388-92. Unexpectedly, targeted deletion of the IL-6 gene in mice induces mature-onset 
obesity, which can be partly reversed by IL-6 replacement93. In addition, chronic exposure 
of skeletal muscle to IL-6 induces insulin resistance although short-term treatment has 
beneficial effects on insulin sensitivity by activation of AMPK and by promoting fatty 
acid oxidation in vivo and in vitro in myotubes94,95. 
 
 
1.9.5 Monocyte chemoattractant protein 1 (MCP-1) 
MCP-1, also termed CCL2, is an 11 kD secreted protein and as the name implies it is a 
potent attractant for monocytes.  Increased secretion of this adipokine has been linked to 
enhanced infiltration of macrophages in obese adipose tissue31,96,97. Both diet-induced and 
genetically obese (ob/ob) mice as well as obese humans display increased expression of 
MCP-1 in adipose tissue31,96-100. Interestingly, disruption of the mcp-1 gene in mice placed 
on a high-fat diet leads to reduced macrophage accumulation, improved insulin resistance 
and attenuation of hepatic steatosis96. Moreover, stimulation of murine fat cells with 
MCP-1 reduces insulin-stimulated glucose uptake97. These findings reveal MCP-1 as an 
important link between obesity and obesity-associated metabolic disturbances. 
 
In WAT, MCP-1 is secreted by cells in the stroma-vascular fraction, e.g. resident 
macrophages (ATM), and by adipocytes, although secretion from isolated adipocytes is 
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significantly lower31,96,99. Whether MCP-1 is released from WAT into the circulation has 
been a matter of debate and at least in humans, MCP-1 primarily appears to work as a 
local factor99. Nevertheless, MCP-1 seems to be an important factor for recruitment of 
monocytes from the circulation and therefore for the regulation of adipose inflammation.  
 
 
1.10 CIDEA 
CIDEA was first identified as an apoptosis-inducing factor in the tumor cell lines 293T 
and MCF7101. It is highly homologous to CIDEB and CIDEC (the latter termed FSP27 in 
mice) however the three proteins show distinct tissue expression patterns101,102. CIDEB is 
most highly expressed in human liver and small intestine as well as in murine liver 
whereas CIDEC is most highly expressed in murine WAT, human heart, colon and small 
intestine101-104. CIDEA expression in mice is highest in brown adipose tissue and detected 
at lower levels in WAT104,105. In contrast, CIDEA is expressed in several human tissues, 
including heart, skeletal muscle, lymph node, brain, bone marrow and WAT. 
 
CIDEA-deficient mice are lean and resistant to obesity and have an increased metabolic 
rate104. This phenotype is most probably due to increased AMPK protein levels and 
activity in brown adipose tissue as well as enhanced fatty acid oxidation in brown 
adipocytes106. In humans, CIDEA seems to have opposite effects. Expression of CIDEA 
in WAT is lower in obese compared to lean subjects and increases after diet-induced 
weight loss107-109. In addition, a coding SNP in the human gene has been associated with 
BMI in a Swedish cohort110. Moreover, low adipose CIDEA expression correlates with 
parameters of insulin resistance and increased CIDEA expression in WAT from cancer 
cachectic patients correlates with decreased fat mass108,109,111,112. At a cellular level, 
CIDEA silencing induces adipocyte lipolysis and TNFα secretion while CIDEA over-
expression enhances FA-oxidation further implicating CIDEA as an important regulator 
in metabolism and obesity-associated inflammation and insulin resistance109,111.  
 
The cellular localization of CIDEA is a matter of controversy. Several groups have 
reported that endogenous and ectopically expressed CIDEA localizes to lipid droplets 
where it increases lipid storage112-114. On the other hand, others have found CIDEA 
localized to the endoplasmic reticulum in brown adipocytes whereas two studies have 
found ectopically expressed CIDEA localized both to the nucleus and the cytosol106,115,116. 
Clearly, there are differences in CIDEA cellular localization between cell lines, different 
tissues and different species although, in human adipocytes CIDEA appears to localize to 
the nucleus as well as to the cytoplasm, possibly to the lipid droplet112,116. 
 
The expression of murine CIDEA has been shown to be induced by PPARα, -γ and the 
PPARγ co-activator (PGC)-1α whereas receptor interacting protein (RIP)-140 negatively 
regulates the murine promoter114,117. Basal activity of the human promoter is regulated by 
Sp1 and Sp3 transcription factors whereas tissue- and cell-specific expression depends on 
CpG methylation118. 
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1.11 TWIST1 
Twist1 is a basic helix-loop-helix (bHLH) transcription factor first identified as a gene 
involved in determining dorsoventral pattern in Drosophila melanogaster119. It shares 
homology with twist2 and the two proteins have partly overlapping functions although 
twist1 has been more extensively studied.  Null mutation in the murine twist1 gene is 
embryonically lethal due to failure of the cranial neural tube to fuse120-122.  In line with the 
murine data, mutations in the human gene lead to Saethre-Chotzen Syndrome 
characterized by facial and skeletal malformations and premature fusion of the skull 
bones (craniosynostosis)120,123. Moreover, twist1 has antiosteogenic functions in vitro 
further supporting an essential role of twist1 in bone formation122,123. Twist1 has also been 
shown to inhibit myogenesis by blocking MyoD and myocyte enhancer factor2 (MEF2), 
transcription factors needed for expression of muscle-specific genes124-126. In addition to 
its role in differentiation, twist1 can induce epithelial-to-mesenchymal transition (EMT) 
associated with cancer progression and metastasis127,128.  
 
Studies in non-adipose cells have shown that twist1 forms homo- or heterodimers with 
other bHLH proteins, which subsequently bind to conserved sequences, termed E-boxes 
(CANNTAG) in the genome. The composition of the twist1 dimer is central for its 
function and therefore twist1 action can vary depending on the dimerizing partner120,125. 
Another level of regulation of twist1 action comes from the phosphorylation status of 
twist1, which affects partner choice and E-box binding affinity120,129,130. 
 
In contrast to twist1 null mice, mice heterozygous for null mutations in the twist1 and -2 
genes are viable, although severely growth retarded. These mice also display high levels 
of pro-inflammatory cytokines in the circulation suggesting a role for twist proteins in 
inflammatory processes131. Moreover, twist1 has been shown to inhibit transcription from 
the murine TNFα promoter by interfering with p65131. Twist1 also mediates suppression 
of inflammation in macrophages and Th1 cells suggesting that twist1 has important anti-
inflammatory actions132,133.  
 
Recently, twist1 was shown to regulate brown adipose tissue metabolism in mice134. 
Interestingly, transgenic mice expressing twist1 in white and brown adipose tissue are 
prone to obesity induced by a high fat diet while heterozygous twist1 knockout mice are 
resistant to obesity. These phenotypes are explained by an altered metabolism in brown 
adipocytes where twist1 interacts with and suppresses the transcriptional activity of PGC-
1α. In conclusion, twist1 regulates a range of cellular functions. The role in both 
inflammatory pathways and brown fat metabolism makes it tempting to speculate that 
twist1 might have important functions in WAT and obesity-associated inflammation as 
well.  
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2 AIMS OF THE PRESENT STUDIES 
 
I. The aim of the first paper was to define the minimal promoter region needed for 
transcription of human CIDEA, and the effect of five SNPs in the promoter region as well 
as the effect of TNFα on transcriptional activity of the promoter. 
 
II. In the second paper, the aim was to investigate the expression pattern of twist1 in 
human WAT as well as other metabolically important organs, and to assess the effect of 
twist1 in vitro silencing on fatty acid oxidation, lipolysis, secretion and mRNA expression 
in human white adipocytes. 
 
III. The aim of the third paper was to investigate twist1 expression in human obesity and 
in relation to different clinical parameters as well as the effect of twist1 on TNFα-
mediated inflammation in human white adipocytes. 
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3 COMMENTS ON MATERIALS AND METHODS USED 
IN THE STUDIES 
 
The experimental methods have been described in detail in paper I, II and III. In the 
next section I will briefly discuss the methods and comment on the use of the method of 
choice. 
 
 
3.1 ETHICAL APPROVAL 
All studies were conducted in accordance with the guidelines of The Declaration of 
Helsinki and approved by the regional ethical committees. The studies were explained 
in detail to each subject and written informed consent was obtained. 
 
 
3.2 SUBJECTS 
Subjects in paper II and III are described in detail in the papers and summarized in 
Table 2. 
 
Table 2. Description of subjects in cohorts from paper II and III. Values are given as mean±SD. WAT = white 
adipose tissue, VLCD = very low calorie diet, w = women, m = men.  
Paper-cohort Gender (w/m) Age BMI Tissue/cell type Study type 
II-cohort 1 
   
WAT, pancreas, liver and skeletal 
muscle qRT-PCR 
II-cohort 2 11/3 37.5±10 29.2±7 WAT and mature fat cells qRT-PCR 
II-cohort 3 10/0 
   
qRT-PCR 
III-cohort 1 non-obese 23/0 39±9 22±1 WAT qRT-PCR 
III-cohort 1 obese 107/0 39±9 39±5 WAT qRT-PCR 
III-cohort 2 10/3 39±7 40±6 WAT (before/after surgery) qRT-PCR 
III-cohort 3 3/9 45±10 38±5 WAT (before/during/after VLCD) qRT-PCR 
III-cohort 4 lean 12/2 41±13 24±2 Sc and om WAT qRT-PCR 
III-cohort 4 obese 23/1 42±10 44±4 Sc and om WAT qRT-PCR 
 
 
3.3 MODEL SYSTEMS AND CELL CULTURES 
In vivo experiments using whole animals, e.g. mice, are of great importance when 
studying the overall effects of complete knock-down of genes. However, in many 
instances the research question might be more specific, concerning only one cell type or 
one specific mechanism. A common way of studying such cellular mechanism in research 
is by the use of cell cultures. 
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In all the present studies the majority of the in vitro experiments were performed in 
human white adipocytes differentiated in vitro from preadipocytes derived from the 
stroma-vascular fraction of human WAT. In paper I we also used adipocytes 
differentiated in vitro from human mesenchymal stem cell (MSC) derived from the 
stroma-vascular fraction and the commercially available murine cell line 3T3-L1.  
 
Commercially available immortalized cell lines like, 3T3-L1, are cells that have changes 
in the cell cycle machinery which occurs either spontaneously, e.g. in tumor cells, or by 
manipulating the cell cycle regulation. The advantage of using such cells is that they grow 
rapidly; they are identical to previous passages and can be frozen and thawed whenever 
needed. Unfortunately, there is no commercially available human fat cell line and most 
studies on human adipocytes have been dependent on the use of primary cell cultures. On 
the other hand, because of changes in the cell cycle machinery, cell lines have a higher 
rate for spontaneous mutations and also an altered phenotype that do not reflect the in vivo 
situations as well as primary cells do. We have therefore tried to use human primary cell 
cultures whenever possible. In the case of some transfection experiments with 
concomitant TNFα stimulations we have chosen to use a murine cell line 3T3-L1 that is 
less vulnerable compared to primary cells.  
 
As can be deduced from the introduction of this thesis there are several important 
differences in the metabolism of mice and humans. Although the important contributions 
from murine studies cannot be disregarded the relevance of such results for humans must 
always be verified. By using human cell system this problem can partly be avoided. 
 
Due to the space limitation in journals the protocols for cell cultures are summarized very 
briefly in all the three papers. In the next section, I have therefore tried to explain in more 
detail how the different cell cultures were performed. 
 
Isolation, culture and differentiation of preadipocytes and WAT-derived MSC have been 
described in detail before135-137. Briefly, WAT obtained from subjects undergoing 
bariatric or cosmetic surgery (liposuction) was washed, cut into small pieces using 
surgical scissors and digested with collagenase for 1 h at 37°C. The collagenase-treated 
cell suspension was centrifuged at 200×g for 10 min and the supernatant, containing 
mature adipocytes and collagenase solution, was removed. The remaining stroma-
vascular fraction (containing both preadipocytes and MSCs) was resuspended in 
erythrocyte lysis buffer for 10 min, filtered through a nylon mesh and centrifuged as 
above. The supernatant was discarded and the pellet resuspended in an inoculation 
medium containing (Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 supplemented 
with 10% fetal bovine serum, 100 µg/mL penicillin-streptomycin) and subsequently 
filtered through a 70 µm pore size filter. The cells were plated at a density of 30000-
50000 cells/cm2 in inoculation medium to allow cell attachment. After 24 h the medium 
was changed to differentiation medium (DMEM/F12 supplemented with 15 mM Hepes, 
100 µg/mL penicillin-streptomycin, 2.5 µg/mL amphotericin B, 66 nM human insulin, 1 
nM triiodo-L-thyroine, 10 µg/mL human transferrin, 33 µM biotin, 17 µM panthotenate, 
100 nM cortisol and 10 µM rosiglitazone (BRL49653)). Rosiglitazone was included the 
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first 3-6 days and then removed from the differentiation media. Medium was changed 
every 2-3 days. 
 
For adipocytes derived from MSC, cells were plated at a density of 160000/cm2 and 
allowed to proliferate in DMEM-low glucose supplemented with 10% fetal calf serum 
and 1% antibiotic-antimycotic solution. In continued passages cells were plated at 
4000/cm2 and passaged at 60-70% confluency. Differentiation was induced by a 
differentiation medium containing DMEM-high glucose, 10% fetal calf serum, 50 µg/mL 
penicillin-streptomycin, 1.25 µg/mL amphotericin B, 15 mM Hepes, 1 nM triiodo-L-
thyroine, 66 nM human insulin, 33 µM biotin, 17 µM panthotenate, 10 µg/mL human 
transferrin, 1 µg/mL dexamethasone, 10 µM rosiglitazone and 0.2 mM 3-isobutyl-1-
1methylxanthine. Three days after induction of differentiation medium was changed to 
post-differentiation medium identical to the differentiation medium but without the 
addition of fetal calf serum, rosiglitazone and 3-isobutyl-1-methylxanthine. Medium was 
changed every 2-3 days and cells were differentiated for 16-20 days.  
 
Proliferation and differentiation of 3T3-L1 cells were performed according to standard 
protocol with one exception. Differentiation of 3T3-L1 cells was performed in a typical 
adipogenic medium consisting of DMEM/F12 Glutamax1, 10% fetal bovine serum, 50 
µg/mL penicillin-streptomycin, 1.25 µg/mL amphotericin B, 10 µg/mL bovine insulin, 1 
µM dexamethasone, 0.2 mM 3-isobutyl-1-1methylxanthine with the addition of 10 µM 
rosiglitazone. 
 
In addition to cell cultures we also used WAT explants in paper III to measure adipokine 
secretion. WAT pieces from a subset of cohort I in paper III were incubated in 4 ml 
Krebs Ringer buffer supplemented with 2% bovine serum albumin (BSA), 1 mg/mL 
glucose and 0.1 mg/mL ascorbic acid for 2 h at 37 °C and adipokine secretion into the 
media was measured by enzyme-linked immunosorbent assay (ELISA). This method 
gives information about the secretion from the WAT, which contains both adipocytes and 
inflammatory cells like macrophages. Another way of assessing adipokine secretion 
would be to use mature adipocyte isolated by collagenase treatment. However, standard 
collagenase-based isolation techniques for mature adipocyte or in vitro differentiated 
adipocytes as well as incubation with BSA have been shown to induce de-differentiation 
and increase expression of pro-inflammatory cytokines in adipocytes138-141. Such effects 
can be avoided by explant culture. Moreover, the short incubation time used in our 
experiments should also minimize the effect of albumin on adipocyte secretion. Although 
it is impossible to elucidate exactly which cells, in the tissue explants, that are responsible 
for the release of adipokines, explant cultures are devoid of the side-effects imposed by 
collagenase treatment and prolonged albumin incubation.  
 
 
3.4 5’ RAPID AMPLIFICATION OF cDNA ENDS (5’RACE) 
In paper I CIDEA transcriptional start site was identified by 5’ RACE. This is a method 
used to obtain full length sequence of RNA transcripts and to characterize the 5’ ends of 
mRNA:s. The same principle can be used for characterization of the 3’ ends of mRNA:s 
and is then referred to as 3’RACE. Messenger RNA:s can be used for the synthesis of a 
 18 
cDNA libraries. Briefly, poly A-tail RNA is reverse transcribed to single strand cDNA 
using reverse transcriptase and a poly-T primer. The second cDNA strand is synthesized 
using DNA polymerase II. RNA is degraded with RNase H, followed by a T4 DNA 
polymerase treatment to generate blunt ends. An adaptor is subsequently ligated using T4 
DNA ligase. In our experiments, we used a ready-made adaptor-ligated Human Adipocyte 
and Adipose Tissue Marathon-Ready cDNA pool. Amplification of CIDEA transcripts 
was performed using an adaptor-specific primer and a gene specific primer. The PCR 
products were gel purified and ligated into a pGEM T Easy vector and ligations were 
transformed into competent bacteria that were plated onto appropriate antibiotic-
containing plates from which colonies were picked and inoculated. DNA from individual 
clones was isolated with a commercially available kit according to standard protocols and 
DNA sequencing was used to confirm the sequence. 
 
 
3.5 REPORTER ASSAYS TO STUDY PROMOTER ACTIVITY 
Luciferase reporter assay is a standard method used to assess promoter activity. In the first 
study we used luciferase reporter constructs to assay activity of the human CIDEA 
promoter.  In paper II, we also used a luciferase reporter construct to assay activity of the 
human IL-6 promoter in the presence or absence of human twist1. Transfections were 
performed in human adipocytes differentiated from WAT-derived MSC or in murine 3T3-
L1 cells using lipofection-based transfections agents as described in the papers.  
 
Although reporter assays efficiently can demonstrate promoter activity there are some 
caveats to this method. First, small changes in promoter activity can be hard to detect 
using this method. Therefore it is possible that haplotype differences in the promoter 
regions might be missed because of lack of sensitivity of the assay. Second, reporter 
constructs lack DNA associated proteins like histones and the chromatin structure. 
Altogether, reporter assays should always be interpreted with caution although they offer 
a relatively straightforward promoter analysis when more advanced techniques like 
chromatin immunoprecipitation (ChIP) are not feasible. 
 
 
3.6 ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA) AND ChIP 
EMSA is a technique used for demonstrating interactions between DNA-binding 
proteins (transcription factors) and DNA. EMSA is performed on nuclear extracts or 
purified recombinant protein and oligonucleotides overlapping a putative binding site 
for the transcription factor of choice. Extracts or proteins are incubated with 
radioactively labeled oligonucleotides and then separated on non-denaturing 
polyacrylamide gels. Binding of proteins to the labeled oligonucleotide will cause a 
slower migration in the gel which can be detected by autoradiography. 
 
ChIP is based on the interaction between DNA-binding proteins and chromatin, which 
are cross-linked using formaldehyde. The cross-linked DNA-protein complexes are 
subsequently isolated and sonicated into smaller fragments (100-1000 bp). These 
fragments are immunoprecipitated using an antibody directed against the protein of 
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interest. In the final step, DNA from the immunoprecipitated DNA-protein complexes is 
extracted and analyzed using conventional PCR (as in paper II), quantitative RT-PCR 
or DNA sequencing. In contrast to EMSA, which can detect putative interactions 
between DNA-binding proteins and oligonucleotides, ChIP is performed on chromatin 
instead of in vitro generated DNA oligonucleotides. This reflects more closely the in 
vivo environment in a cell. However, ChIP analysis is highly dependent on the protein-
DNA interactions at the specific time-point when cells were cross-linked and is 
therefore highly dependent on the environment in the nucleus at the point of cross-link. 
Another caveat with ChIP is the requirement of large quantities of cells and the 
dependence on sensitive and specific antibodies. 
 
In paper II we used ChIP to demonstrate binding of twist1 to regions in the human IL-
6, MCP-1 and TNFα promoters.  
 
 
3.7 QUANTITATIVE REVERSE TRANSCRIPTASE (RT)-PCR  
Quantitative RT-PCR is used for measuring the mRNA levels of a specific gene of 
interest. Messenger RNA levels can be used as an indirect measure of the activity of a 
gene and mRNA levels are often (although not always) correlated with the protein 
levels of the same gene. In brief, total RNA from tissue or cells is extracted and reverse 
transcribed to complementary DNA (cDNA) using random or oligo dT primers and 
reverse transcriptase. The cDNA is subsequently used in a PCR reaction with a Taq 
polymerase and primers overlapping exon-exon boundaries of the gene of interest. In 
real time PCR, the PCR reaction is monitored in real-time using a PCR instrument 
which measures the amount of PCR product based on fluorescence in the reaction. With 
each PCR cycle more fluorescence is generated and this is directly proportional to the 
amount of PCR product in the reaction. SYBR Green and Taqman are two commonly 
used technologies used for real time PCR. 
 
SYBR Green is a non-specific dye for double stranded (ds) DNA that fluoresces when it 
is bound to dsDNA. The SYBR Green dye detects specific and unspecific products as 
well as primer-dimers equally well, which can generate false-positive results. This can 
be avoided by careful primer design and the use of melting curves and gel 
electrophoresis to confirm amplification of a single product.  
 
In Taqman assays, the primers are delivered by the manufacturer together with 
fluorescently-labeled probes that are complementary to a sequence in the target PCR 
product. The probes are labeled with a fluorophore and a quencher that absorbs the 
fluorescence when the probe has not bound. During elongation of the single stranded 
DNA the target-bound probe will be degraded by the Taq polymerase at the same time 
releasing the fluorophore from the quencher and fluorescence is emitted. 
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In both SYBR Green and Taqman assays the result of the PCR run is a Ct value used 
for calculating the relative or the absolute target mRNA levels based on the ∆∆Ct 
method or a standard curve, respectively. The ∆∆Ct method, which is easier and faster, 
can be used if the amplification efficiency of the reference and target genes is close to 
100%. Taqman assays are guaranteed to give 100% amplification efficiency whereas 
SYBR Green assays need to be optimized using dilution series of cDNA to ensure that 
target and reference genes are amplified equally effective. In our analysis, we have used 
the ∆∆Ct method. For analyzes of large clinical samples we used SYBR Green assays 
and for evaluation of mRNA expression in in vitro experiments we used Taqman 
assays. Ct values of the target genes were normalized to the reference gene GAPDH (for 
in vitro experiments), or 18S rRNA (clinical samples), which were amplified in parallel 
reactions. In addition another reference gene, LRP10, previously shown to be a reliable 
reference gene in WAT, was used to confirm all results142. The relative mRNA 
expression levels were calculated according to the formula 2-ΔΔCt = arbitrary units 
(A.U.) where the target Ct is normalized to a reference and relative to a calibrator. 
 
Other methods for measuring mRNA include Northern blot and in situ hydridization. 
None of these methods are as sensitive as RT-PCR and Northern blot is only semi-
quantitative whereas in situ hydridization is qualitative.  
 
3.8 RNA INTERFERENCE (RNAi) 
To study the role of twist1 in human in vitro differentiated adipocytes we employed RNAi to 
silence twist1 using small interfering RNA (siRNA). This method was first described in 
Caenorhabditis elegans where introduction of small double stranded RNA was able to 
completely block the expression of the target mRNA:s that the siRNA was complementary 
to143,144. In paper II and III we have used a siRNA from Dharmacon, Thermo Fisher 
Scientific, CO, USA. This product consist of a pool of four different siRNA:s targeting 
different sequences in the same mRNA, in our case twist1. The exact protocol for siRNA 
treatment is described in the papers. The optimal transfection conditions were determined in 
separate titration experiments. To control for unspecific effects of siRNA treatment, control 
cells were treated with a negative control siRNA. These oligonucleotides have no known 
similarities to human sequences.  Cells were incubated for 48 hours post-transfection and 
conditioned media was collected for analyzes of adipokine and glycerol release. Cells were 
then lysed for RNA or protein extraction as described below. 
 
 
3.9 LIPOLYSIS MEASUREMENTS 
The effect of twist1 silencing on lipolysis was assessed in paper II. Lipolysis, measured 
as glycerol release, was quantified using a bioluminescence method in conditioned media 
from human in vitro differentiated adipocytes145,146. In brief, this method is based on two 
competing reactions shown below.  
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ATP + glycerol                        glycerol-1-phosphate + ADP 
 
ATP + luciferin + O2                oxyluciferin + AMP + PPi + CO2+ light 
 
 
When both enzymes (glycerol kinase and luciferase) and both substrates (glycerol and 
luciferin) are present the two reactions will compete for the available ATP. Increasing 
concentrations of glycerol will shift the reaction towards generation of more glycerol-1-
phosphate. This in turn will lead to decreased generation of oxyluciferin and a decay in 
the emitted light. The decrease in light can be monitored and used as a measure of 
glycerol concentration in the solution.  
 
As previously discussed, lipolysis generates one glycerol and three NEFA molecules per 
molecule of TAG. NEFAs can be reused in the synthesis of TAGs but glycerol cannot be 
converted to glycerol 3-phosphate in the adipocyte. Therefore, lipolysis is preferentially 
measured as the release of glycerol rather than the release of NEFA. On the other hand, 
by measuring both glycerol and NEFA release it is possible to determine the rate of 
NEFA re-esterification. 
 
 
3.10 PROTEIN MEASUREMENTS 
Western blot and ELISA are two qualitatively different methods to detect proteins in a 
sample. Western blot is performed on denatured proteins whereas ELISA is preformed on 
native proteins. The identity of the protein in Western blot is verified by antibody recognition 
as well as by the migration of the denatured protein compared to a known standard. In 
ELISA, the detection of protein is completely dependent on antibody-antigen interaction. On 
the other hand, competitors can be used in ELISA to verify the specificity of the antibody. 
Both methods are highly dependent on specific antibodies. ELISA is preferably used as a 
screening technique as this method is relatively more simple and faster than Western blot. 
Commercial ELISAs include a standard curve for the protein of interest thereby allowing a 
quantitative estimate of the concentration of the studied protein in an unknown sample. 
 
In the papers presented here we used Western blot to detect protein expression in tissue or cell 
lysates whereas ELISA was used for detection of secreted proteins. Western blot was used for 
detection of proteins in protein lysates from human in vitro differentiated adipocytes treated 
with siRNA (paper II) or from WAT samples from non-obese and obese subjects in cohort I 
(paper III). The protocol has been described in the papers.  
 
Secretion of adipokines into conditioned medium was measured using ELISA kits. 
Conditioned media was collected from human in vitro differentiated adipocytes treated with 
siRNA or from WAT samples. Assays were performed according to the manufacturer’s 
instructions. 
 
Luciferase 
Glycerol kinase 
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3.11 FATTY ACID OXIDATION/PALMITATE OXIDATION 
Fatty acids are broken down in the mitochondria in a cyclic multi-step reaction where two 
carbons are released in the form of one acetyl-CoA. Each cycle in the fatty acid oxidation 
releases one molecule of acetyl-CoA until the whole fatty acid chain is broken down. The 
acetyl-CoA can be used in the citric acid cycle. The end product of the citric acid cycle is 
GTP, NADH, ubiquinol and carbon dioxide (CO2).  
 
In our assays fatty acid oxidation was assessed by the ability of adipocytes to oxidate 
palmitate added to the cell culture. The rate of palmitate oxidation is measured as the sum 
of released CO2 and palmitate oxidation metabolites into the medium, as described in 
paper II. One of the rate-limiting enzymes in the fatty acid oxidation is carnitine 
palmitoyltransferase (CPT) 1, which transfers long-chain fatty acids over the outer 
mitochondrial membrane by binding them to carnitine. In our experimental set-up 
carnitine is added in excess to the incubation medium. 
 
 
3.12 INSULIN SENSITIVITY  
Insulin sensitivity was assessed by the homeostasis model of assessment of insulin 
resistance (HOMA-IR) in paper III. This insulin resistance test is calculated based on 
fasting insulin levels and blood glucose levels according to the formula: ((fasting plasma 
insulin [mU/L] * fasting plasma glucose [mM/L]) / 22.5). A normal HOMA value should 
be approximately 1. 
 
The gold standard for determining insulin resistance is the hyperinsulinemic euglycemic 
clamp. However, this test is tedious and expensive and not suitable for routine clinical 
practice. 
 
In addition to HOMA-IR and hyperinsulinemic euglycemic clamp, insulin resistance can 
be assessed using fasting insulin levels in the circulation or by a glucose tolerance test. 
During the glucose tolerance test the fasting subject receives 75 g glucose orally and 
blood glucose levels are measured under the following 2 hours. These methods are used 
in both experimental science and in routine clinical practice to determine insulin 
resistance. However, in our cohorts, insulin sensitivity was only assessed by the HOMA-
IR. 
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4 RESULTS AND DISCUSSION 
 
4.1 TRANSCRIPTIONAL CONTROL OF HUMAN CIDEA (PAPER I) 
In the first paper we identified a single CIDEA transcript from an adipocyte and WAT 
cDNA library. This transcript corresponds to a previously published CIDEA transcript 
NM_001279 and has a 14 bp long 5’untranslated region (5’UTR). On the other hand, 
murine transcripts of CIDEA in liver has substantially longer 5’UTR:s, possibly 
indicating a species- or tissue-specific regulation of CIDEA117. Using bioinformatics we 
were able to identify an evolutionary conserved region between the rat, mouse and human 
CIDEA promoter. This conserved region also overlapped with a putative CpG island in 
both the murine and the human promoters. CpG islands are genomic regions with a high 
frequency of cytosine and guanine nucleotides in a linear sequence. The cytosine 
nucleotide can be methylated to form 5-mehylcytosine, a modification that is associated 
with inactive genes. CpG islands are typically found in the promoter region of genes and 
therefore play an important role in transcriptional regulation. Altogether, the conservation 
between species and the presence of putative CpG islands in both the murine and the 
human promoter suggest an important role for this region in the transcriptional control of 
CIDEA. During the preparation of the first paper a study on the transcriptional regulation 
of human CIDEA was published by Li et al118. In that study the authors showed that 
methylation of a CpG island is involved in the tissue-specific expression pattern of 
CIDEA in liver, spleen, stomach, heart and adipose tissue as well as in three different cell 
lines. The CpG island identified by us overlaps with the CpG island identified by Li et al.   
 
To further assess the transcriptional control of human CIDEA we generated deletion 
fragments of the promoter. Using a luciferase-based reporter system we were able to 
identify the minimal promoter needed for transcription. This promoter overlapped with 
the minimal promoter identified by Li et al.  
 
Results from our group has shown that a polymorphism in the coding region of CIDEA is 
associated with BMI in a Swedish cohort110. In the same study, several polymorphisms in 
the promoter region for CIDEA was also described110. In the present paper we 
investigated the effect of five SNPs located in the CIDEA promoter on the transcription of 
CIDEA. Using luciferase constructs of the human CIDEA promoter we could not detect 
any significant differences between the three haplotypes investigated. It is possible that 
the changes in transcriptional activity attributed by these SNPs are too small to be 
detected in our assays. In addition, we cannot exclude the possibility that these SNPs are 
important in vivo when linked to other SNPs and the chromatin structure. 
 
TNFα attenuates the expression of CIDEA in human adipocytes109. To further explore 
this regulation we studied the transcriptional activity of deletion fragments in the presence 
or absence of TNFα. As expected, TNFα markedly reduced CIDEA promoter activity in 
both human and murine adipocytes. PPARγ has been shown to regulate transcription of 
CIDEA in murine liver. However, we were unable to detect any effect of a PPARγ agonist 
on the transcriptional activity of the human promoter in adipocytes, at least after a 24 h 
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incubation. Analysis of the activity of mutation fragments in the presence of TNFα 
showed that TNFα regulation was confined to a region between –244 and –123, relative 
the transcriptional start site, in the CIDEA promoter, which overlaps with a putative NF-
κB binding site. Interestingly, mutation of this NF-κB binding site attenuated the 
transcriptional effect of TNFα. Moreover, TNFα induced binding between nuclear 
proteins and an oligonucleotide overlapping the NF-κB site in a gel-retardation assay. 
Incubation with nuclear extracts from adipocytes, treated with TNFα and an inhibitor of 
NF-κB, reduced the protein-oligonucleotide complexes whereas treatment of adipocytes 
with an inactive form of the NF-κB inhibitor had no effect on the interaction between 
nuclear proteins and the oligonucleotide. No interaction was observed when nuclear 
extracts were incubated with an oligonucleotide overlapping another region of the CIDEA 
promoter without any predicted NF-κB site.   
 
In conclusion, in paper I we were able to define the minimal promoter needed for basal 
transcription of human CIDEA. In addition we defined a region in the promoter regulated 
by TNFα that overlaps an NF-κB binding site and probably contributes to the 
transcriptional repression of CIDEA by TNFα.  
 
 
4.2 A POSSIBLE INFLAMMATORY ROLE OF TWIST1 IN HUMAN WHITE 
ADIPOCYTES (PAPER II) 
Preliminary results from our laboratory, on WAT expression from lean and obese subjects 
showed that twist1 was significantly higher expressed in lean compared to obese subjects. 
Twist1 is also highly expressed in brown and white adipose tissue in mice and regulates 
brown fat function by interaction with PGC1α134. Therefore, in the second paper we set 
out to investigate the role of twist1 in human white adipocytes. We measured the 
expression levels in metabolically important organs, in different cells from human WAT 
as well as during in vitro differentiation of adipocytes. Compared to twist2, which was 
detectable in skeletal muscle, liver, pancreas and WAT, twist1 was selectively expressed 
in WAT. Twist1 expression was higher in adipocytes compared to adipose derived-
endothelial cells and macrophages and increased during in vitro differentiation of human 
adipocytes. In vitro silencing of twist1 in human adipocytes reduced fatty acid oxidation 
and the expression of CPT1, a key enzyme involved in fatty acid oxidation. Furthermore 
expression of the brown fat cell regulator, PGC1α, was reduced whereas lipolysis as well 
as expression of PLIN and HSL were unaffected by twist1-silencing. Altogether, these 
results suggested that twist1 is needed to maintain fatty acid oxidation which is in contrast 
to results obtained in mice where twist1 impairs fatty acid oxidation and brown adipose 
tissue function by inhibiting PGC1α action. On the other hand, there is no previous study 
on the functional role of twist1 in murine or human WAT which makes it difficult to 
speculate whether the divergence in fatty acid oxidation is caused by tissue-specific or 
species-specific differences. In human WAT, fatty acid oxidation accounts for only a 
small percentage of the whole-body fatty acid oxidation. Therefore the impact of twist1 
on WAT fatty acid oxidation probably is of less importance. 
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Previous work from twist1 and twist2 heterozygous knockout mice has indicated a role 
for these transcription factors in inflammatory pathways. Using ChIP and in vitro 
silencing of twist1 in cultured adipocytes we were able to demonstrate a role for twist1 in 
the regulation of the pro-inflammatory factors TNFα, IL-6 and MCP-1 but not of 
adiponectin. First; silencing of twist1 reduced the secretion and mRNA expression of IL-6 
and MCP-1 and second; twist1 was able to bind to the promoters of TNFα, IL6 and MCP-
1 suggesting that twist1 is needed for expression of several pro-inflammatory cytokines. 
In addition, over expression of human twist1 in murine 3T3-L1 cells reduced the 
transcriptional activity from a human IL-6 promoter construct, further supporting a role in 
the regulation of this cytokine. Curiously, our results in human adipocytes suggest that 
twist1 is needed for the expression of IL-6 and MCP-1 whereas the data from 3T3-L1 
cells suggest that twist1 can reduce the transcriptional activity of the human IL-6 
promoter. Previous studies show that twist1 is able to inhibit NF-κB signaling in COS 
cells by interacting with p65131.  In light of these divergent data we believe that the correct 
interpretation is that twist1 can regulate the expression of pro-inflammatory cytokines and 
that the outcome of this regulation is highly dependent on the cell types, species and the 
present nuclear proteins at each specific time point. In D. melanogaster and in bone 
development the action of twist1 is tightly coupled to the protein levels of twist1 and even 
small changes in expression can alter the choice of hetero-dimerizing partners. Different 
dimers will recruit different transcription factors, which will modify the chromatin 
structure in different ways and thereby the expression of target genes120. Therefore it 
seems reasonable that the effect of twist1 in adipocytes is strongly correlated with the 
particular protein levels of twist1 and possibly with protein levels of its dimerizing 
partners. 
 
Altogether, we have for the first time demonstrated a role for twist1 in human white 
adipocytes. Twist1 mRNA expression is highest in WAT compared to other metabolically 
important organs including liver, pancreas and skeletal muscle, possibly suggesting a role 
in human WAT. The expression of twist1 is also highest in the adipocytes compared to 
other cells in the tissue. In contrast to its function in murine brown adipose tissue twist1 
represses neither fatty acid oxidation nor the expression of genes involved in fatty acid 
oxidation in human adipocytes. In fact, twist1 seems to be essential to maintain a normal 
fatty acid oxidation in human white adipocytes. Twist1 does however regulate the 
expression of pro-inflammatory cytokines, TNFα, IL-6 and MCP-1. 
 
 
4.3 TWIST1 IN HUMAN WHITE ADIPOSE TISSUE AND OBESITY (PAPER 
III) 
 
Because of its proposed role in brown fat function and inflammation we hypothesized that 
twist1 might be involved in obesity-associated inflammation. In paper III we measured 
twist1 mRNA expression in WAT from non-obese and obese subjects and correlated the 
expression levels with markers for insulin resistance and inflammation. Twist1 was 
significantly more highly expressed in non-obese subjects and the expression increased 
after weight reduction induced either by a diet or surgery. The expression was also higher 
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in WAT from the sc depot compared to omental depot and low expression of twist1 in sc 
WAT was associated with low insulin sensitivity, large adipocyte volume and low 
adiponectin expression. Furthermore, we divided our subjects into four different groups 
based on the obesity status and the morphology of the WAT, e.g. hyperplastic or 
hypertrophic WAT. Interestingly, twist1 expression was highest in the hyperplastic non-
obese group and lowest in hypertrophic obese group. In addition, secretion of TNFα and 
MCP-1 from WAT pieces was significantly higher in subjects with low twist1 mRNA 
expression compared to a group of subjects with high twist1 expression. Altogether, these 
data show that twist1 expression is reduced in obesity and that low twist1 expression in sc 
WAT associates with a metabolically more unfavorable profile characterized by increased 
secretion pro-inflammatory markers.  
 
Results from our previous work in human adipocytes (paper II) suggested that twist1 is 
needed for the expression of several pro-inflammatory genes, including IL-6 and MCP-1, 
and would imply that reduced twist1 expression in adipocyte could be beneficial to reduce 
inflammation147. At first glance, the previous results seemed to contradict our present 
results where twist1 associated with a lean and metabolically healthier profile. Therefore 
we set up an experiment where we tried to mimic the in vivo environment of WAT in 
obesity by reducing twist1 expression using siRNA and at the same time stimulating 
adipocytes with TNFα. Interestingly, in this context where twist1 expression was reduced 
and TNFα levels were high, twist1 down regulation augmented the effect of TNFα on 
MCP-1 expression and secretion. Moreover, twist1 silencing also accelerated the TNFα-
induced increase in IL-6, RelA and TNFR1 mRNA expression. These results show that 
twist1 can attenuate the actions of TNFα in adipocytes and are therefore in accordance 
with our clinical data suggesting that low twist1 expression in an environment with 
elevated TNFα levels may have pathological rather than beneficial consequences. The 
repressive effect of twist1 on TNFα-induced gene expression is also in agreement with 
previous work in nonadipose cells131. Taken together we believe that twist1 regulates the 
effects of TNFα in at least two ways; 1) when TNFα levels are low, twist1 is needed to 
retain basal transcription of several cytokines and chemokines that may be necessary for 
normal tissue function, and 2) when TNFα levels are high, twist1 has protective effects on 
the TNFα-induced cyto- and chemokine expression.  
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
As the title of this thesis implies, the aim of the presented work was to identify novel 
genes in WAT associated with obesity. In addition to obesity, the two genes studied in 
this thesis appear to play a role in WAT inflammation since they are either controlled by 
TNFα, regulate the action of TNFα or both. 
 
CIDEA is a relatively unknown protein. The first data on the CIDE-family 
(CIDEA,CIDEB and CIDEC/FSP27) suggested that CIDE-proteins are involved in 
apoptosis101. The first indication that CIDEA might be involved in metabolic processes 
came from CIDEA null mice, which were lean and resistant to obesity, most likely due to 
an increased BAT function104,106. In contrast to these data, CIDEA expression is decreased 
in human WAT in obesity109. Moreover, CIDEA expression is increased in cancer 
cachexia and correlates with reduced fat mass111.  Altogether data from mice and human 
suggest that CIDEA has species-specific functions on metabolism. Moreover, CIDEA 
expression is decreased by TNFα and in vitro silencing of CIDEA in human white 
adipocytes results in enhanced TNFα secretion indicating that CIDEA and TNFα cross-
talk109. In paper I, we defined the minimal promoter region needed for transcription of 
CIDEA and defined a region in the promoter that is important for TNFα regulation. 
Together with previously published data these results confirm the regulation of CIDEA by 
TNFα and also suggest that high TNFα levels in obesity could be a contributing factor to 
the reduced CIDEA expression in human WAT. 
 
Although several papers have been published on the function of CIDEA it still is not clear 
what the role of this protein is in adipocytes, where the protein is localized and what 
proteins CIDEA interacts with. Some studies have shown that CIDEA is localized to the 
lipid droplet and enhances lipid droplet size suggesting a role in the regulation lipid 
storage112-114.  Interestingly, a recent study from our laboratory showed that CIDEA is 
localized both to the cytosol and the nucleus. Moreover, CIDEA was shown to bind to 
nuclear receptors suggesting that CIDEA might be involved in transcriptional regulation 
as well. On the other hand, the physiological outcome of this interaction has not been 
investigated.  
 
It is possible that post-translational modifications of CIDEA can alter its cellular 
localization and thereby the function of the protein. Further studies investigating these 
mechanisms and the correlation between such modifications and the cellular localization 
of CIDEA, CIDEA function and potential interacting proteins would contribute to the 
understanding of the physiological function of CIDEA in adipocytes. 
 
 
Twist1 is a transcription factor with well-described functions in developmental processes 
in D. melanogaster, differentiation, EMT as well as inflammation. However, the role in 
WAT has not been described before. In paper II and III we showed that twist1 is 
expressed in human WAT, primarily in the adipocytes, and that low twist1 expression 
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associates with a metabolically more unfavorable profile (high BMI, reduced insulin 
sensitivity, and increased MCP-1 and TNFα secretion). The association of twist1 with 
obesity has subsequently been confirmed in a French cohort comprising lean and obese 
subjects (unpublished data from Karine Clement’s group, Paris, France). In contrast to 
murine data, twist1 seems to be needed to maintain normal fatty acid oxidation in human 
white adipocytes. Twist1 also regulates inflammatory pathways in human adipocytes and 
low expression of this transcription factor makes the adipocyte more sensitive to the pro-
inflammatory effects of TNFα, one of the key regulators of obesity-related inflammation.  
 
It is tempting to speculate that manipulation of twist1 expression in obese subjects to 
levels similar to those seen in non-obese subjects could have beneficial effects on WAT 
inflammation and perhaps also on fatty acid oxidation, which could influence whole-body 
metabolism. The first step in this approach would be to investigate the effect of in vitro 
over-expression of twist1 in our human adipocyte cell system. It is essential that such 
studies be performed in human cell systems and not in rodent cells, given that there are 
important species-specific differences in twist1 function in inflammation and metabolism. 
In fact, during the last period of my PhD studies we have set up a series of experiments 
where twist1 was over expressed in human in vitro differentiated adipocytes using an 
adenoviral construct. RNA from these experiments was subsequently analyzed by gene 
expression arrays and the data are now being processed for evaluation.  
 
Another way of inducing twist1 expression would be to activate its expression. Acute 
TNFα stimulation has been shown to induce twist1 expression through the NF-κB 
signaling pathway in immortalized mouse fibroblasts. However, since TNFα is already 
high in the obese state this regulation is probably not functional during these 
circumstances and implies that chronic TNFα stimulation has different effects than acute 
stimulation131. Stimulation of macrophages with the anti-inflammatory cytokine 
interferon (IFN) α for two days also induces twist1 expression, via activation of a Tyro 3 
receptor kinase termed Axl133. On the other hand, because of the delayed response in 
twist1 expression this activation probably involves other proteins and signaling pathways 
as well. It has been shown that insulin-like growth factor (IGF)-1, via activation of 
mitogen-activated protein kinases (MAPK), is able to induce the expression of twist1 in 
NIH-3T3 fibroblast whereas another study demonstrated that treatment with a PPARδ-
agonist is able to stimulate twist1 expression in brown adipocytes134,148. In order to use 
any of these factors to stimulate twist1 expression the effects would first need to be 
confirmed in human adipocytes. It should also be noted that twist1 function is highly 
dependent on the choice of dimerizing partner and thus the identity of these proteins in 
human adipocytes needs to be assessed. Last but not least, since over expression of twist1 
has been confirmed in several tumors and tumor cell lines the effect of over expression for 
EMT and tumor progression would need to be thoroughly assessed.  
 
A further apparent and very relevant experiment is to perform ChIP sequencing on twist1 
in human adipocytes to define target genes regulated by this transcription factor. Such 
experiment could be performed in cell cultures with or without over expression of twist1 
or with or without in vitro silencing of twist1. A comparison of such ChIP sequencing 
data with gene expression data from experiments with in vitro over-expression of twist1 
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in adipocytes could provide novel insight into the function of twist1 in human adipocytes 
and also identify new target genes or pathways controlled by this transcription factor. It 
would also be interesting to compare twist1 target genes in the lean and obese state and 
with or without TNFα stimulation. Such experiments could also be used to examine the 
identity of the twist1 dimerizing proteins under the different conditions. 
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